Published in Transl Oncol on April 01, 2015
Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins. Mol Cell Proteomics (2016) 0.76
Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes Cancer (2016) 0.75
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Molecular genetics of prostate cancer. Genes Dev (2000) 5.18
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J (2003) 5.11
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med (2003) 4.30
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32
p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res (2000) 3.31
New paths in human cancer serology. J Exp Med (1998) 3.12
Management of cancer of the prostate. N Engl J Med (1994) 3.04
The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol (1993) 2.95
Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol (2001) 2.87
Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (1998) 2.83
ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Curr Biol (2009) 2.82
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA (1995) 2.70
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst (1999) 2.35
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85
Proteins required for centrosome clustering in cancer cells. Sci Transl Med (2010) 1.35
European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br J Cancer (1999) 1.09
DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. Br J Cancer (2011) 1.05
PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer (2009) 0.97
Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract (2002) 0.92
PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol (2013) 0.91
Aurora-A kinase interacting protein 1 (AURKAIP1) promotes Aurora-A degradation through an alternative ubiquitin-independent pathway. Biochem J (2007) 0.85
Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother (2011) 0.84
TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells. Cancer Cell Int (2013) 0.84
Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci (2001) 0.84
Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen. Clin Chim Acta (2011) 0.83
Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma. Histopathology (2011) 0.83
Loss of ASP but not ROPN1 reduces mammalian ciliary motility. Cytoskeleton (Hoboken) (2011) 0.82
Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks). Can Urol Assoc J (2011) 0.76